To further gain insight into the mechanism by which alisertib enhances the antitumor activity of BI-2536 in SCLC cells, we first assessed RAD51 foci formation upon treatment with BI-2536 and alisertib, both as monotherapies and in combination. This evidence concerns the gene RAD51 and small cell lung carcinoma.